Sign in
Taking people in United StatesPhase 2

Tests cell therapy with or without pembrolizumab for metastatic skin melanoma

Tests immune cells from a patient's tumor, with or without pembrolizumab, in metastatic skin melanoma.

Key facts

Who runs it
National Cancer Institute (NCI)
Where
Bethesda, United StatesSee the site
Trial code
Registry title
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Status
Recruiting
Phase
Phase 2
People taking part
53 people, planned
Started
4 Dec 2015
Expected to end
16 Jun 2029
Type of study
Interventional, 3 groups
Treatments tested
  • young TIL
  • Pembrolizumab
  • Aldesleukin
  • Fludarabine
  • Cyclophosphamide
Record updated
20 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 72 with metastatic melanoma of the skin who have already had at least one treatment. It tests TIL cell therapy with aldesleukin, with or without pembrolizumab.

Age
18 to 72 years
Sex
All sexes can join.
Disease stage
Measurable metastatic melanoma with at least one lesion that can be removed to grow TIL cells. The disease must be getting worse at the time of treatment. Up to 3 small, symptom-free brain metastases (each less than 1 cm (0.4 in)) are allowed.
Earlier treatment
Must have had at least one earlier therapy for metastatic melanoma, and any earlier systemic therapy must be finished. People who took tyrosine kinase inhibitors can join with stable disease.
Biomarker or test result
Blood tests must be negative for HIV antibody, hepatitis B antigen and hepatitis C antibody. If hepatitis C antibody is positive, HCV RNA must be negative.

Main reasons for not taking part

  • Pregnant or nursing people of child-bearing potential
  • Primary immunodeficiency, or current opportunistic infections
  • Major organ autoimmune disease in the past
  • Taking systemic steroids, or other investigational drugs
  • Heart or lung problems as described in the criteria (coronary revascularization, ischemic symptoms, low LVEF or FEV1)

The registry criteria, word for word

Show all 31 criteriaShow less

Who cannot take part

  • Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)
  • Concurrent systemic steroid therapy
  • Grade 3 or 4 major organ Immune-related Adverse Events (IRAEs) clinically attributed to anti PD-1/PD-L1 monotherapy. Previously screened participants that experience these IRAEs after resection for creation of TIL are excluded from Arm 2, but may be eligible for assignment to Arm 3. NOTE: For the purposes of this protocol, thyroid is not considered a major organ
  • Patients who are receiving any other investigational agents
  • Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease)
  • Active systemic infections requiring anti-infective treatment, coagulation disorders or any other active major medical illnesses
  • History of major organ autoimmune disease
  • History of severe immediate hypersensitivity reaction to any of the agents used in this study
  • History of coronary revascularization or ischemic symptoms
  • For select patients with a clinical history prompting cardiac evaluation: last LVEF less than or equal to 45%
  • Individuals of child-bearing potential who are pregnant or nursing because of the potentially dangerous effects of the treatment on the fetus or infant
  • For select patients with a clinical history prompting pulmonary evaluation: known FEV1 less than or equal to 50%

Other criteria

  • -INCLUSION CRITERIA:
  • Measurable metastatic melanoma with at least one lesion that is resectable for TIL generation
  • Confirmation of diagnosis of metastatic melanoma by the Laboratory of Pathology of NCI
  • Patients must have received at least one prior therapy for metastatic melanoma
  • Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible
  • Greater than or equal to 18 years and less than or equal to 72 years
  • All participants must sign a written informed consent
  • All participants must be willing to sign a durable power of attorney
  • Clinical performance status of ECOG 0 or 1
  • Patients of both sexes must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
  • Serology:; Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus are less responsive to the experimental treatment and more susceptible to its toxicities.); Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative
  • Individuals of child-bearing potential must be willing to undergo a pregnancy test prior to the start of treatment because of the potentially dangerous effects of the treatment on the fetus
  • Individuals of child-bearing potential (IOCBP) must agree to use highly effective contraception (hormonal, intrauterine device [IUD, abstinence, surgical sterilization starting at the time of study entry, for the duration of study therapy, and 12 months after the last dose of combined chemotherapy; Individuals that can father children must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and for 4 months after the last dose of combined chemotherapy. We also will recommend individuals that can father children ask their partners to be on highly effective birth control (hormonal, intrauterine device (IUD), surgical sterilization); NOTE: IOCBP is defined as any female who has experienced menarche and who has not undergone successful surgical sterilization or who is not postmenopausal; NOTE: Certain malignancies may secrete hormones that produce false positive pregnancy tests. Serial blood testing (e.g. HCG measurements) and/ or ultrasound may be performed for clarification; IOCBP must not donate, or retrieve for their own use, ova from the time of study treatment initiation and throughout the study treatment period, and for at least 12 months after the final study drug(s) administration. Individuals that can father children must not freeze or donate sperm for at least 12 months after the final study drug(s) administration
  • Nursing participants must be willing to discontinue nursing from study treatment initiation through 4 months after the last dose of the study drug(s)
  • Hematology; Absolute neutrophil count greater than 1000/mm3 without the support of filgrastim/biosimilar; WBC greater than or equal to 2500/mm3; Platelet count greater than or equal to 800,000/mm3; Hemoglobin > 8.0 g/dl
  • Chemistry; Serum ALT/AST less than or equal to 2.5 times ULN; Serum Creatinine less than or equal to 1.6 mg/dl; Total bilirubin less than or equal to 1.5 mg/dl, except in patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL
  • Patients must have completed any prior systemic therapy at the time of enrollment
  • Patients must demonstrate progressive disease at the time of treatment. (Note: Patients who have received tyrosine kinase inhibitors (e.g. vemurafinib) may be treated if they present with stable disease at the time of treatment)
  • Patients must be co-enrolled in protocol 03-C-0277

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 72 years old?

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: NCI/Surgery Branch Recruitment CenterTaking people

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

Cell therapy is an experimental cancer therapy. It takes young tumor infiltrating lymphocytes (Young TIL) cells from a person s tumors and grows them in a lab. Then they are returned to the person. Researchers think adding the drug pembrolizumab might make the therapy more effective.

Objective:

To test if adding pembrolizumab to cell therapy is safe and effective to shrink melanoma tumors.

Eligibility:

People ages 18-72 years with metastatic melanoma OF THE SKIN

Design:

Participants will be screened with:

Physical exam

CT, MRI, or PET scans

X-rays

Heart and lung function tests if indicated

Blood and urine tests

Before treatment, participants will have:

A piece of tumor taken from a biopsy or during surgery in order to grow TIL cells

Leukapheresis: Blood flows through a needle in one arm and into a machine that removes white blood cells.

The rest of the blood returns through a needle in the other arm.

An IV catheter placed in the chest for getting TIL cells, aldesleukin, and pembrolizumab (if assigned)

Participants will stay in the hospital for treatment. This includes:

Daily chemotherapy for 1 week

For some participants, pembrolizumab infusion 1 day after chemotherapy

TIL cell infusion 2-4 days after chemotherapy, then aldesleukin infusion every 8 hours for up to 12 doses

Filgrastim injections to help restore your blood counts

Recovery for 1-3 weeks

After treatment, participants will:

Take an antibiotic and an antiviral for at least 6 months, as applicable

If assigned, have pembrolizumab treatment every 3 weeks for 3 more doses. They may have another round.

Have 2-day follow-up visits every 1-3 months for 1 year and then every 6 months

The 3 groups in the trial

  • 1/ACT TILTreatment being tested

    Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (IL-2)

    Treatment: young TIL, Aldesleukin, Fludarabine, and Cyclophosphamide

  • 2/ACT TIL + PembroTreatment being tested

    Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (IL-2) + pembrolizumab

    Treatment: young TIL, Pembrolizumab, Aldesleukin, Fludarabine, and Cyclophosphamide

  • 3/ACT TIL (Pembro contraindicated)Treatment being tested

    Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young TIL + highdose aldesleukin (IL-2)

    Treatment: young TIL, Aldesleukin, Fludarabine, and Cyclophosphamide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Plain-language title
Tests cell therapy with or without pembrolizumab for metastatic skin melanomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT02621021, who can take part
Record updated
20 August 2026